proPSA

Description…

ProPSA (-2), or [-2]proPSA, is a PSA isoform which has a leader peptide (-2) amino acids at its N terminal region and does not interact with ACT or alpha-2-macroglobulin or spermidine and therefore is detected as a separate isoform. ProPSA is produced primarily in the peripheral zone of the prostate gland and therefore is very useful in distinguishing between prostate cancer patients with PSA range of 2-10, from those who have BPH. Percent proPSA is the ratio of proPSA to free PSA. In July 2012 the FDA approved an assay measuring levels of [-2]proPSA for monitoring and diagnostic purposes.

The following organs have data associated with this biomarker…

Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.

• Delta Radiomics Improves Pulmonary Nodule Malignancy Prediction in Lung Cancer Screening.
• Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial.
• Molecular markers of prostate cancer.
• Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo.
• Validation of a blood protein signature for non-small cell lung cancer.

• NCBI Gene record for KLK3, also known as PSA, with links to protein isoforms of PSA
• 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY
• Genecards record for human kallikrein 3, also known as PSA
• FDA Medical Device description of Hybritech p2PSA assay
• National Cancer Institute News Note
• NCI Fact Sheet for Prostate-Specific Antigen (PSA) Test
• Draft Directional Insert
• Summary of Safety and Effectiveness Data (SSED)